🕵️ AEON Biopharma, Inc. ($AEON)
SEC insider & ownership activity, last 12 months · CIK 1837607 · every row links its SEC filing
Insiders were quiet over the last 12 months – no open-market buys or sells. Daewoong CO.,LTD. ("DWC") added 0.9% → 50.0%. One red-flag 8-K in the window: Delisting notice (3.01), Mar 31, 2026.
Insider flow
0 buyers, $0 (0 lots) · 0 sellers, $0 (0 lots)
No open-market insider transactions in the last 12 months.
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Daewoong CO.,LTD. ("DWC") | 50.0% | 13D | Jan 21, 2026 | filing ↗ | |
| Daewoong Pharmaceutical Co. Ltd ("DWP") | 49.8% | 13D | Jan 21, 2026 | filing ↗ | |
| Stonepine Capital Management, LLC | 9.9% | Class A | 13G | Jul 21, 2026 | filing ↗ |
| Stonepine Capital, L.P. | 9.9% | Class A | 13G | Jul 21, 2026 | filing ↗ |
| Stonepine GP, LLC | 9.9% | Class A | 13G | Jul 21, 2026 | filing ↗ |
| Jon M. Plexico | 9.9% | Class A | 13G | Jul 21, 2026 | filing ↗ |
| Chernett Jorey | 9.9% | 13G | May 30, 2025 | filing ↗ | |
| Dauntless Investment Group, LLC | 9.7% | 13G | Mar 3, 2025 | filing ↗ | |
| Bigger Michael | 6.1% | 13G | Jan 8, 2025 | filing ↗ | |
| The Palmisano Family, LLC | 5.7% | 13D | Jul 25, 2024 | filing ↗ | |
| Robert J Palmisano | 5.7% | 13D | Jul 25, 2024 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Other events (8.01) | Jul 23, 2026 | filing ↗ |
| Material agreement (1.01) | Jul 13, 2026 | filing ↗ |
| Other events (8.01) | Jul 13, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 13, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 17, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 14, 2026 | filing ↗ |
| Earnings (2.02) | May 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 14, 2026 | filing ↗ |
| Delisting notice (3.01) | Mar 31, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 31, 2026 | filing ↗ |
| Earnings (2.02) | Mar 30, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 30, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 6, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Jan 21, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jan 21, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jan 21, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 21, 2026 | filing ↗ |
| Other events (8.01) | Jan 21, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 21, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 12, 2026 | filing ↗ |
| Material agreement (1.01) | Dec 15, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Dec 15, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Dec 15, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 15, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Dec 4, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 4, 2025 | filing ↗ |
| Earnings (2.02) | Nov 14, 2025 | filing ↗ |